MedTrace Logo

Examination of Efficacy and Safety of Baricitinib in RA Patients

NCT03755466 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-21

No results posted yet for this study

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Baricitinib treatment for 12 months
2. Biologics treatment for 12 months
3. Tofacitinib treatment for 12 months

Conditions

Interventions

DRUG

"Baricitinib", "olumiant®"

To examine the effects of baricitinib in RA patients

DRUG

"Biologics"

To examine the effects of biologics in RA patients

DRUG

Tofacitinib 5 MG [Xeljanz]

To examine the effects of tofacitinib in RA patients

Sponsors & Collaborators

  • Shinshu University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2023-11-20
Completion
2025-11-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03755466 on ClinicalTrials.gov